The safety and efficacy trial of sequential administration with AP (Doxorubicin/Paclitaxel) followed by weekly Paclitaxel as preoperative chemotherapy for breast cancer: SBCCSG-07
Phase 2
Completed
- Conditions
- Primary breast cancer
- Registration Number
- JPRN-UMIN000000504
- Lead Sponsor
- Saitama Breast Cancer Clinical Study Group (SBCCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. severe complication 2. suspicious of infection 3. past history of allergic reaction to cremophor EL (polyoxyethylated caster oil) or polysorbate 4. Pregnant or lactating women 5. Doctor's decision for exclusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method